Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Anlotinib in HER2-Negative Advanced Breast Cancer
NCT07520760Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, anlotinib in breast cancer, sponsored by Sun Yat-sen University. Started Apr 2026; status: recruiting.
02
Drugs
eribulinanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07520760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520760.